EJNMMI Research

Table 1 LPS effects

From: Quantification of [¹¹C]PBR28 data after systemic lipopolysaccharide challenge

Model	Parameter	LPS Effect
Model	Parameter	Partial η²	95% CI	Overall (%)	MABs (%)	HABs (%)
AIF AUC	AUC	0.87**	0.47–0.92	− 32.6	− 30.0	− 38.1
2TCM	V_T	0.87**	0.45–0.92	46.7	56.4	38.9
2TCM-1k	V_T	0.56*	0.03–0.74	24.3	10.4	34.6
MA-1	V_T	0.87**	0.46–0.92	44.9	53.3	37.8
SIME	BP_P	0.89**	0.53–0.93	81.9	94.1	61.5
SUV, 60–90 min	SUV	0.35	0.00–0.61	− 9.9	− 1.4	− 19.8
SUV, 90–120 min	SUV	0.07	0.00–0.39	− 1.5	8.7	− 13.6
SUVR, 60–90 min	SUVR	0.34	0.00–0.61	− 3.0	− 1.4	− 5.5
SUVR, 90–120 min	SUVR	0.15	0.00–0.46	− 1.3	− 0.7	− 4.3

LPS effect % = [(Post-LPS − Pre-LPS)/Pre-LPS] × 100. Partial η² effect size interpretation: “Small” ≤ 0.09, “Moderate” = 0.10–0.24, “Large” ≥ 0.25. 95% CI 95% confidence interval for the partial η² effect size at p = .05. Significant LPS effects are noted
*p ≤ .05
**p < .01

Back to article page